Herbert Smith Freehills advises Zhejiang Cangnan Instrument Group on Hong Kong listing 史密夫斐尔律师事务所为浙江苍南仪表集团股份有限公司香港上市提供法律服务

Leading global law firm Herbert Smith Freehills has advised Zhejiang Cangnan Instrument Group on its H Share listing on the Hong Kong Stock Exchange.

领先的国际律师事务所史密夫斐尔律师事务所为浙江苍南仪表集团股份有限公司全球发售H股并在香港上市提供法律服务。

Zhejiang Cangnan Instrument Group is a leading precision measurement instrument manufacturer in China with over 40 years' industry experience. As China increases its gas consumption in recent years in replacement of coal, the company has recorded significant growth backed by its advanced proprietary technology and has expanded into residential gas meters and nuclear power precision equipment.

ABCI Capital Limited, a Hong Kong incorporated and wholly owned subsidiary of Agricultural Bank of China, was the sole sponsor of the listing.

"We are delighted to have assisted Zhejiang Cangnan Instrument Group on its Hong Kong listing," said Beijing partner Tom Chau. "In one of the busiest years for Hong Kong listings, the strength of our Greater China team has now assisted a number of Mainland companies and banking advisers in listing on the exchange."

Zhejiang Cangnan Instrument Group's listing closely follows a number of Hong Kong listings on which the firm's Greater China equity capital markets team advised in 2018, including last week's Hong Kong listing of the Chinese biopharma company Shanghai Junshi Biosciences, the first "3+H" issuer achieving dual listing on HKSE and NEEQ and the first H share issuer to take advantage of the exchange's newly relaxed listing rules for pre-revenue biotech companies.

Tom and partner Zhong Wang led a cross-office team advising Zhejiang Cangnan Instrument Group, assisted by senior associates Lawrence Wang, Isaac Chen, Sherry Lai, legal specialist Kathy Zhang and legal analysts Ian Zhong and Iris Zhu.

浙江苍南仪表集团股份有限公司（以下简称“苍南仪表”）是中国领先的精密测量仪表制造商，拥有逾40年的行业经验。随着中国近年来增加天然气的使用以替代煤炭，苍南仪表借助先进的专利技术而取得了业务表现的大幅攀升，并开拓了民用燃气表产品和核电精密仪器市场。

中国农业银行香港全资子公司农银国际融资有限公司担任此次上市的独家保荐人。

“我们很荣幸能够协助苍南仪表在香港上市”，史密夫斐尔北京办公室合伙人邹兆麟律师表示。“过去一年港股IPO创新纪录，我们大中华区团队凭借领先的实力，成功就多项上市项目为中国内地企业或金融机构提供法律服务。”

史密夫斐尔大中华区股权资本市场团队在2018年完成多个上市项目，包括上周上市的中国生物制药公司——上海君实生物医药科技有限公司，君实是首家新三板及H股上市的“3+H”公司，也是首家根据港交所新近放宽的未产生营业收入的生物科技公司上市规则实现 上市的H股公司。

史密夫斐尔为苍南仪表提供法律服务的北京、香港团队由邹兆麟和王重两位合伙人领导，高级律师王蓓良、陈敏、黎翠芬、高级法律经理张凯西、法律经理钟文彬、朱梓萱提供支持。